Amgen-Astellas Japan JV preps for launch
This article was originally published in Scrip
Amgen Astellas BioPharma will begin operations on 1 October but the senior management team of the new Japanese joint venture between Astellas and Amgen is giving little away at this stage on the specific plans for the business.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.